Navigation Links
Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Date:5/22/2012

ntly reported rat and dog models confirm Unigene's prior preclinical studies.  These results support the Company's plans to commence Phase 1 clinical testing in obese subjects next year and indicate that, if these results can be reproduced in humans, UGP281 could potentially offer a new and very exciting treatment option in an area that clearly needs new and better treatments."

Nozer Mehta, PhD, Unigene's VP, Research and Development stated, "We are extremely pleased with our progress with UGP281 and continue to build an encouraging preclinical data set for our lead proprietary metabolic peptide."  Dr. Mehta continued, "UGP281's selective receptor-binding is anticipated to result in a cleaner and more attractive safety profile relative to several of the small molecule drug candidates or drug combinations currently, or previously, in development.  We continue to further differentiate UPG281 from other potentially competitive, peptide-based drugs and drug candidates and believe we will have the opportunity to optimally position UGP281 in this rapidly growing and significantly underserved market space."

Unigene is currently preparing for the submission of its Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and expects to be able to commence Phase 1 clinical testing of UGP281 in the first half of 2013.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering peptide drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets inclu
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
3. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
4. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
7. Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
8. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
9. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
10. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
11. Fujifilm Demonstrates the Latest Advancements of Synapse® PACS at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , August 22, 2014 ... http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the addition of ...  report to their offering.       ... an essential instrument for any modern science ... weighing of materials. It can be broadly ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 /PRNewswire/ ... ) has announced the addition of the  ... to their offering.       (Logo: ... room with a sterile environment in a ... It is equipped with technically advanced equipment, ...
(Date:8/22/2014)... WASHINGTON , Aug. 22, 2014 ... Obamacare that modify the religious "accommodation" but still ... drugs that have an abortifacient effect, including Plan ... "week after pill"). The Obama Administration also announced ... religious, closely held, for-profit corporations. The ...
Breaking Medicine Technology:Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs 2
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Back-to-school time provides ... that fits into the family schedules, an expert suggests. ... child,s school year can also be the start of ... Richards, a professor of kinesiology at the University of ... release. With kids, extracurricular activities likely to build ...
(Date:8/22/2014)... 22, 2014 Dayton Children's Hospital broke ground ... part of a $141 million campus renewal. Renderings ... were unveiled to the public. , The new patient ... will create a campus that meets the needs of patients, ... care spaces will embody Dayton Children’s unique patient care mission ...
(Date:8/22/2014)... CLEVELAND Renal artery stenting to open blockages ... have historically been excluded from modern clinical trials, ... e-published in Catheterization and Cardiovascular Interventions ... Interventions (SCAI). , University Hospitals Case Medical Center,s ... and Professor of Medicine, Case Western Reserve University ...
(Date:8/22/2014)... Menstrual leaks risk stains and embarrassment, especially ... that there needed to be a better way to ... in design variations, the Safety Net optimizes protection during ... embarrassment and promotes peace of mind. The pad serves ... original design was submitted to the Fort Lauderdale office ...
(Date:8/22/2014)... who use reduced-nicotine cigarettes don,t smoke more to make ... a new study. This means they don,t inhale ... The month-long study included 72 adult smokers, aged ... emission levels of 1.2 milligrams (mg) each for one ... the next three weeks. In each of those ...
Breaking Medicine News(10 mins):Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2
... response to the growing,demand for solutions to ... United,States, a group of entrepreneurs has established ... consulting,firm with over 25 years experience in ... implement pharmaceutical care, and,"Inspire Pharmacists to Practice ...
... Quantify Competitive Treatment Landscape and Support Model-Based Drug ... ... 27 Pharsight,Corporation (Nasdaq: PHST ), a leading provider of ... that it has licensed its public-source Type II,Diabetes meta- database to ...
... Oxygen Community Praises Congressman for Formally Opposing Deep,Cuts ... March 26 Pacific Pulmonary,Services - Ukiah Center, ... and services to more than 200 patients in ... Thompson (CA-1st) to,meet with patients, physicians and technicians ...
... Actuaries Unveil Election 2008 Resources for Voters on ... The American Academy of,Actuaries said the most ... address the program,s long-term financing issues.,According to the ... income from payroll taxes, and Medicare must,rely also ...
... in 2008, -- IND filing for liquid formulation NGX-1998 expected in first half of ... ... under EMEA review for neuropathic pain ... Calif., March 26 NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused on developing ...
... Hillenbrand,Industries, Inc. (NYSE: HB ) (the "Company") announced ... in connection with its previously,announced cash tender offer to ... Notes due 2009 (CUSIP No. 431573AD6). The tender offer ... February 29, 2008 (the,"Offer to Purchase") and the related ...
Cached Medicine News:Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:Pharsight Signs New Diabetes Meta-Database Customer 2Health News:Pharsight Signs New Diabetes Meta-Database Customer 3Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 2Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 8Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: